Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related death in males and females in the world. It is of immediate importance to develop novel therapeutics. Human ribonucleotide reductase (RRM1/RRM2) has an essential role in converting ribonucleoside diphosphate to 2′-deoxyribonucleoside diphosphate to maintain the homeostasis of nucleotide pools. RRM2 is a prognostic biomarker and predicts poor survival of CRC. In addition, increased RRM2 activity is associated with malignant transformation and tumor cell growth. Bioinformatics analyses show that RRM2 was overexpressed in CRC and might be an attractive target for treating CRC. Therefore, we attempted to search novel RRM2 inhibitors by using a gene expression signature-based approach, connectivity MAP (CMAP). The result predicted GW8510, a cyclin-dependent kinase inhibitor, as a potential RRM2 inhibitor. Western blot analysis indicated that GW8510 inhibited RRM2 expression through promoting its proteasomal degradation. In addition, GW8510 induced autophagic cell death. In addition, the sensitivities of CRC cells to GW8510 were associated with the levels of RRM2 and endogenous autophagic flux. Taken together, our study indicates that GW8510 could be a potential anti-CRC agent through targeting RRM2.

[1]  J. Wright,et al.  The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Cao,et al.  Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  T. Beißbarth,et al.  A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets , 2011, International journal of cancer.

[4]  Sangeeta Khare,et al.  Guidelines for the use and interpretation of assays formonitoring autophagy (3rd edition) , 2016 .

[5]  Y. Yen.  Ribonucleotide reductase subunit one as gene therapy target: commentary re: M-Y. Cao et al., Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin. Cancer Res., 9: 4304-4308, 2003. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  R A Knight,et al.  Classification of cell death: recommendations of the Nomenclature Committee on Cell Death , 2005, Cell Death and Differentiation.

[7]  Yusuke Nakamura,et al.  A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage , 2000, Nature.

[8]  Lijun Xue,et al.  Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer. , 2011, Cancer research.

[9]  Thomas Lengauer,et al.  Dissection of the Inflammatory Bowel Disease Transcriptome Using Genome-Wide cDNA Microarrays , 2005, PLoS medicine.

[10]  Jean Lu,et al.  Functional Module Connectivity Map (FMCM): A Framework for Searching Repurposed Drug Compounds for Systems Treatment of Cancer and an Application to Colorectal Adenocarcinoma , 2014, PloS one.

[11]  Michael Karin,et al.  Inflammation and colon cancer. , 2010, Gastroenterology.

[12]  Robert Clarke,et al.  Guidelines for the use and interpretation of assays for monitoring autophagy , 2012 .

[13]  R A Knight,et al.  Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009 , 2005, Cell Death and Differentiation.

[14]  S. Itzkowitz,et al.  Intestinal inflammation and cancer. , 2011, Gastroenterology.

[15]  Lijun Xue,et al.  Metastasis-Suppressing Potential of Ribonucleotide Reductase Small Subunit p53R2 in Human Cancer Cells , 2006, Clinical Cancer Research.

[16]  Michal A. Kurowski,et al.  Transcriptome Profile of Human Colorectal Adenomas , 2007, Molecular Cancer Research.

[17]  H. Clevers,et al.  Wnt, stem cells and cancer in the intestine , 2005, Biology of the cell.

[18]  C. Bokemeyer,et al.  Current standards and new trends in the primary treatment of colorectal cancer. , 2011, European journal of cancer.

[19]  Y. Yen,et al.  Autophagy induction causes a synthetic lethal sensitization to ribonucleotide reductase inhibition in breast cancer cells , 2015, Oncotarget.

[20]  Lijun Xue,et al.  Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. , 2007, Clinical colorectal cancer.

[21]  J. Wright,et al.  The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. , 1998, Cancer research.

[22]  Y. Yen,et al.  Targeting ribonucleotide reductase for cancer therapy , 2013, Expert opinion on therapeutic targets.

[23]  Y. Yen,et al.  Ribonucleotide reductase inhibitors and future drug design. , 2006, Current cancer drug targets.

[24]  Y. Yen,et al.  p53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer. , 2010, Oncology Letters.

[25]  Lijun Xue,et al.  Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers , 2012, Clinical science.

[26]  T. Barrette,et al.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. , 2007, Neoplasia.

[27]  P. Reichard,et al.  Ribonucleotide reductases. , 1998, Annual review of biochemistry.

[28]  Avi Ma'ayan,et al.  Lean Big Data integration in systems biology and systems pharmacology. , 2014, Trends in pharmacological sciences.

[29]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[30]  Alan Cantor,et al.  RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[32]  Y. Yen,et al.  Reciprocal regulation of autophagy and dNTP pools in human cancer cells , 2014, Autophagy.

[33]  Dennis B. Troup,et al.  NCBI GEO: mining tens of millions of expression profiles—database and tools update , 2006, Nucleic Acids Res..